Document Detail

Increased nitrotyrosine in exhaled breath condensate in cystic fibrosis.
MedLine Citation:
PMID:  11491165     Owner:  NLM     Status:  MEDLINE    
Exhaled nitric oxide (ENO), a marker of inflammation in airway diseases is decreased in cystic fibrosis (CF) patients, perhaps because nitric oxide (NO) is metabolized to oxidative end-products. A stable product, 3-nitrotyrosine, may indicate local formation of reactive nitrogen species. Whether NO metabolites in exhaled breath condensate may be increased in CF patients was investigated. The fractional concentration of ENO (Feno), nitrotyrosine and oxides of nitrogen in exhaled breath condensate from 36 stable CF patients were compared to 14 normal subjects using an enzyme immunoassay and fluorescence assay. Nitrotyrosine levels in breath condensate were increased significantly in stable CF patients, compared with normal subjects (25.3 +/- 1.5 versus 6.3 +/- 0.8 ng x mL(-1), p<0.0001). There was an inverse correlation between the levels of nitrotyrosine and the severity of lung disease. Feno levels were significantly lower in CF patients than in normal subjects (4.4 +/- 0.3 versus 5.6 +/- 0.4 (parts per billion), p<0.05). No correlation was found between nitrotyrosine and Feno levels in CF. There was no significant difference in the levels of nitrite and nitrate between CF patients and normals. The elevation in nitrotyrosine may reflect increased formation of reactive nitrogen species such as peroxynitrite or direct nitration by granulocyte peroxidases, indicating increased oxidative stress in airways of cystic fibrosis patients.
B Balint; S A Kharitonov; T Hanazawa; L E Donnelly; P L Shah; M E Hodson; P J Barnes
Related Documents :
6614395 - Ferrokinetic and hematologic studies in cystic fibrosis patients.
2231825 - Cranial electrostimulation (ces) use in the detoxification of opiate-dependent patients.
18195585 - Pulmonary complications in adult patients with cystic fibrosis.
20457545 - Serum-surfactant sp-d correlates inversely to lung function in cystic fibrosis.
2157375 - Spontaneous release of angiotensin converting enzyme and interleukin 1 beta from periph...
17516875 - Medical management of urinary stone disease.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The European respiratory journal     Volume:  17     ISSN:  0903-1936     ISO Abbreviation:  Eur. Respir. J.     Publication Date:  2001 Jun 
Date Detail:
Created Date:  2001-08-08     Completed Date:  2001-12-18     Revised Date:  2013-05-23    
Medline Journal Info:
Nlm Unique ID:  8803460     Medline TA:  Eur Respir J     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  1201-7     Citation Subset:  IM    
Dept of Thoracic Medicine, Imperial College School of Medicine at the National Heart and Lung Institute, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Breath Tests*
Cystic Fibrosis / diagnosis*
Lung Volume Measurements
Oxidative Stress
Reactive Nitrogen Species / analysis
Reference Values
Tyrosine / analogs & derivatives*,  analysis*
Reg. No./Substance:
0/Reactive Nitrogen Species; 3604-79-3/3-nitrotyrosine; 55520-40-6/Tyrosine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C.
Next Document:  Nasal potential difference measurements in patients with atypical cystic fibrosis.